Oxidative phosphorylation inducers fight pathological angiogenesis

M Pilar Bayona-Bafaluy; Olivia Esteban; Javier Ascaso; Julio Montoya; Eduardo Ruiz-Pesini

doi:10.1016/j.drudis.2019.03.014

Oxidative phosphorylation inducers fight pathological angiogenesis

Drug Discov Today. 2019 Sep;24(9):1731-1734. doi: 10.1016/j.drudis.2019.03.014. Epub 2019 Mar 14.

Authors

M Pilar Bayona-Bafaluy¹, Olivia Esteban², Javier Ascaso², Julio Montoya³, Eduardo Ruiz-Pesini⁴

Affiliations

¹ Departamento de Bioquímica, Biología Molecular y Celular, Universidad de Zaragoza, Zaragoza, Spain; Aragón Health Research Institute (IIS Aragón), Zaragoza, Spain; Centro de Investigaciones Biomédicas en Red de Enfermedades Raras (CIBERER), Spain. Electronic address: pbayona@unizar.es.
² Aragón Health Research Institute (IIS Aragón), Zaragoza, Spain; Department of Ophthalmology, Hospital Clínico Universitario 'Lozano Blesa', Zaragoza, Spain.
³ Departamento de Bioquímica, Biología Molecular y Celular, Universidad de Zaragoza, Zaragoza, Spain; Aragón Health Research Institute (IIS Aragón), Zaragoza, Spain; Centro de Investigaciones Biomédicas en Red de Enfermedades Raras (CIBERER), Spain.
⁴ Departamento de Bioquímica, Biología Molecular y Celular, Universidad de Zaragoza, Zaragoza, Spain; Aragón Health Research Institute (IIS Aragón), Zaragoza, Spain; Centro de Investigaciones Biomédicas en Red de Enfermedades Raras (CIBERER), Spain; Fundación ARAID, Zaragoza, Spain. Electronic address: eduruiz@unizar.es.

PMID: 30880173
DOI: 10.1016/j.drudis.2019.03.014

Abstract

Pathological mutations in subunits of the oxidative phosphorylation (OXPHOS) system, or inhibitors of this biochemical pathway, increase the production of vascular endothelial growth factor (VEGF) and pathological angiogenesis. In many angiogenesis-related diseases, such as retinal, rheumatoid diseases, or cancer, OXPHOS dysfunction can be found. Thus, enhancing OXPHOS might be a promising therapeutic approach for pathologic angiogenesis.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Angiogenesis Inhibitors / pharmacology
Animals
Humans
Mitochondrial Diseases / drug therapy*
Neoplasms / drug therapy
Neovascularization, Pathologic / drug therapy*
Neovascularization, Pathologic / etiology*
Retinal Diseases / drug therapy
Retrospective Studies
Rheumatic Diseases / drug therapy
Vascular Endothelial Growth Factor A / metabolism

Substances

Angiogenesis Inhibitors
Vascular Endothelial Growth Factor A